{"entity":{"id":"nct07093814","kind":"trial","name":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","aka":[],"tldr":"A phase 1/2 trial of VRT106 in glioma & glioblastoma, run by Guangzhou Virotech Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma is a phase 1/2 interventional study registered as NCT07093814 by Guangzhou Virotech Pharmaceutical Co., Ltd., with 42 participants planned, started 2025-09-02 and due to reach its primary completion in 2028-12-31. Interventions recorded: VRT106.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07093814","url":"https://clinicaltrials.gov/study/NCT07093814"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["guangzhou-virotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07093814","phase":"1/2","setting":"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","sponsor":"Guangzhou Virotech Pharmaceutical Co., Ltd.","started":"2025-09-02","startedType":"actual","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07093814/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"guangzhou-virotech","kind":"company","name":"Guangzhou Virotech Pharmaceutical","route":"/companies/guangzhou-virotech/"}]}}